Hexokinase II and Its Major Partners: Role in Cancer Progression
Abstract
Full Text:
PDFReferences
H. Ardehali, Y. Yano, R.L. Printz, S. Koch, R.R. Whitesell, J.M. May, et al. J Biol Chem. 1996; 271: 1849–52p.
K.K. Arora, D.M. Parry, P.L. Pedersen. J Bioenerg Biomembr. 1992; 24: 47–53p.
K.K. Arora, P.L. Pedersen. J Biol Chem. 1988; 263: 17422–8p.
D.C. Bay, D.A. Court. Biochem Cell Biol. 2002; 80: 551–62p.
E. Blachly-Dyson, E.B. Zambronicz, W.H. Yu, V. Adams, E.R. McCabe, J. Adelman, et al. J Biol Chem. 1993; 268: 1835–41p.
E. Bustamante H.P. Morris, P.L. Pedersen. J Biol Chem. 1981; 256: 8699–704p.
E. Bustamante, P.L. Pedersen. Proc Natl Acad Sci USA. 1977; 74: 3735–9p.
E. Bustamante, P. Pediaditakis, L. He, J.J. Lemasters. Biochem Biophys Res Commun. 2005; 334: 907–10p.
M.C. Cesar, J.E. Wilson. Arch Biochem Biophys. 1998; 350: 109–17p.
M.C. Cesar, J.E. Wilson. Arch Biochem Biophys. 2004; 422: 191–6p.
Z. Chen, W. Lu, C. Garcia-Prieto, P. Huang. The Warburg effect and its cancer therapeutic implications, J Bioenerg Biomembr. 2007; 39: 267–74p.
M. Colombini. Mol Cell Biochem. 2004; 256–257: 107–15p.
C.V. Dang. Links between metabolism and cancer, Genes Dev. 2012; 26: 877–90p.
R.J. DeBerardinis, C.B. Thompson. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012; 148: 1132–44p.
P.L. Felgner, J.L. Messer, J.E. Wilson. J Biol Chem. 1979; 254: 4946–9p.
T. Gauthier, C. Denis-Pouxviel, J.C. Murat. Int J Biochem. 1990; 22: 419–23p.
J.F. Graham, C.J. Cummins, B.H. Smith, P.L. Kornblith. Neurosurgery. 1985; 17: 537–42p.
E.S. Kropp, J.E. Wilson. Biochem Biophys Res Commun. 1970; 38: 74–9p.
A.J. Levine, A.M. Puzio-Kuter. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes, Science. 2010; 330: 1340–4p.
W. Lu, P. Huang. Glycolytic pathway as a target for tumor inhibition, The Tumor Microenvironment Book. 2010, 91–118p.
S.P. Mathupala, C. Heese, P.L. Pedersen. J Biol Chem. 1997a; 272: 22776–80p.
S.P. Mathupala, A. Rempel, P.L. Pedersen. J Biol Chem. 1995; 270: 16918–25p.
S.P. Mathupala, A. Rempel, P.L. Pedersen. J Bioenerg Biomembr. 1997b; 29: 339–43p.
S.P. Mathupala, A. Rempel, P.L. Pedersen. J Biol Chem. 2001; 276: 43407–12p.
R.A. Nakashima, P.S. Mangan, M. Colombini, P.L. Pedersen. Biochemistry. 1986; 25: 1015–21p.
P.L. Pedersen, S. Mathupala, A. Rempel, J.F. Geschwind, Y.H. Ko. Biochim Biophys Acta. 2002; 1555: 14–20p.
P.L. Pedersen. Prog Exp Tumor Res. 1978; 22: 190–274p.
R.L. Printz, H. Osawa, H. Ardehali, S. Koch, D.K. Granner. Biochem Soc Trans. 1997; 25: 107–12p.
R. Majeed, A. Hamid, Y. Qurishi, A.K. Saxena. Therapeutic targeting of cancer cell metabolism: role of metabolic enzymes, oncogenes and tumor suppressor genes, Cancer Sci Ther. 2012; 4.9p.
I.A. Rose, J.V. Warms. J Biol Chem. 1967; 242: 1635–45p.
I.A. Rose, J.V. Warms. Arch Biochem Biophys. 1982; 213: 625–34p.
S.P. Mathupala, K. YH, P.L. Pedersen. Hexokinase II: Cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria, Oncogene. 2006; 25: 4777–86p.
D. Sui, J.E. Wilson. Arch Biochem Biophys. 1997; 345: 111–25p.
D. Sui, J.E. Wilson. Biochem Biophys Res Commun. 2004; 319: 768–73p.
H. Tedeschi, K.W. Kinnally, C.A. Mannella. J Bioenerg Biomembr. 1989; 21: 451–9p.
H.J. Tsai, J.E. Wilson. Arch Biochem Biophys. 1995; 316: 206–14p.
H.J. Tsai, J.E. Wilson. Arch Biochem Biophys. 1996; 329: 17–23p.
H.J. Tsai, J.E. Wilson. Arch Biochem Biophys. 1997; 338: 183–92p.
O. Warburg, F. Dickens, Kaiser Wilhelm-Institut fu¨ r Biologie B. The Metabolism of Tumours: Investigations from the Kaiser-Wilhelm Institute for Biology. Berlin-Dahlem, Constable: London; 1930.
DOI: https://doi.org/10.37628/ijcbcp.v3i2.210
Refbacks
- There are currently no refbacks.